iptacopan
Term · Oncology and biomedicine · MLC-T-ONC-014566
An orally available, small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, iptacopan binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as paroxysmal nocturnal hemoglobinuria (PNH).
| Identifier | MLC-T-ONC-014566 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | factor B inhibitor LNP023 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014566",
"term": "iptacopan",
"field": "Oncology and biomedicine",
"definition": "An orally available, small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, iptacopan binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as paroxysmal nocturnal hemoglobinuria (PNH).",
"synonyms": [
"factor B inhibitor LNP023"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/iptacopan/"
}
Record 9,563 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.